- Home
- IVVD vs GNLX Comparison
IVVD vs GNLX Comparison
Compare IVVD & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVVD
- GNLX
- Stock Information
- Founded
- IVVD 2020
- GNLX 2001
- Country
- IVVD United States
- GNLX United States
- Employees
- IVVD N/A
- GNLX N/A
- Industry
- IVVD Biotechnology: Pharmaceutical Preparations
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- IVVD Health Care
- GNLX Health Care
- Exchange
- IVVD Nasdaq
- GNLX Nasdaq
- Market Cap
- IVVD 116.8M
- GNLX 103.6M
- IPO Year
- IVVD 2021
- GNLX 2023
- Fundamental
- Price
- IVVD $0.44
- GNLX $2.27
- Analyst Decision
- IVVD Strong Buy
- GNLX Strong Buy
- Analyst Count
- IVVD 4
- GNLX 4
- Target Price
- IVVD $7.89
- GNLX $18.25
- AVG Volume (30 Days)
- IVVD 981.7K
- GNLX 142.7K
- Earning Date
- IVVD 11-14-2024
- GNLX 11-14-2024
- Dividend Yield
- IVVD N/A
- GNLX N/A
- EPS Growth
- IVVD N/A
- GNLX N/A
- EPS
- IVVD N/A
- GNLX N/A
- Revenue
- IVVD $11,564,000.00
- GNLX $8,000.00
- Revenue This Year
- IVVD N/A
- GNLX N/A
- Revenue Next Year
- IVVD $486.65
- GNLX N/A
- P/E Ratio
- IVVD N/A
- GNLX N/A
- Revenue Growth
- IVVD N/A
- GNLX N/A
- 52 Week Low
- IVVD $0.40
- GNLX $1.60
- 52 Week High
- IVVD $5.20
- GNLX $16.60
- Technical
- Relative Strength Index (RSI)
- IVVD 29.58
- GNLX 38.68
- Support Level
- IVVD $0.57
- GNLX $2.13
- Resistance Level
- IVVD $0.51
- GNLX $2.80
- Average True Range (ATR)
- IVVD 0.06
- GNLX 0.20
- MACD
- IVVD -0.01
- GNLX -0.04
- Stochastic Oscillator
- IVVD 13.30
- GNLX 14.21
About IVVD Invivyd Inc.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.